Sign In
Buy JNJ
$231.29
+2.90 (+1.27%)
At Close: Jun 22, 2026
The 5 Safest Dividend Kings Have Raised Their Dividends for Over 50 Years
08:43am, Friday, 06'th Mar 2026
Investors love dividend stocks because they provide dependable passive income streams and an excellent opportunity for solid total return.
Dividend Aristocrats in a Shaky Market: KO, PG, JNJ, and 2 Others Built to Last
08:02am, Friday, 06'th Mar 2026
The market's fear gauge tells the story clearly. The VIX hit 21.15 as of March 4, 2026, up 29.4% in a single month.
First Look: Oil Spike, Warsh Nomination, JNJ Drug Win, MCD Buzz
07:40am, Friday, 06'th Mar 2026
Stock News Oil jumps on Hormuz shutdown fears: United States Oil Fund (USO) tracked crude's surge past $80 as tanker traffic in the Strait of Hormuz stalled and
Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors
06:45pm, Thursday, 05'th Mar 2026
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $239.63, denoting a -2.31% move from the preceding trading day.
Johnson & Johnson units to pay $65 million to settle Tracleer antitrust class action
05:51pm, Thursday, 05'th Mar 2026
Two Johnson & Johnson units have agreed to pay $65 million to settle a proposed antitrust class action by health plans and others claiming they were overcharged for the pulmonary hypertension drug
Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression – free survival and overall survival versus standard of care regimens 83.3% of patien
US FDA approves JNJ's blood cancer drug
02:21pm, Thursday, 05'th Mar 2026
The U.S. Food and Drug Administration on Thursday approved Johnson & Johnson's treatment for a type of blood cancer, making it the third drug cleared under the agency's new spe
Johnson & Johnson launches website for direct-to-consumer sales
06:07pm, Wednesday, 04'th Mar 2026
Johnson & Johnson has launched a website to sell some of its drugs directly to U.S. patients who either don't have insurance or pay for their drugs out of pocket.
Top 3 Dividend Aristocrat Stocks to Buy for Strong Returns in 2026
11:31am, Wednesday, 04'th Mar 2026
Volatility is again picking up, and it's a good idea to focus more on safety.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
10:00am, Wednesday, 04'th Mar 2026
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Johnson & Johnson (JNJ) Presents at TD Cowen 46th Annual Health Care Conference Transcript
02:02pm, Tuesday, 03'rd Mar 2026
Johnson & Johnson (JNJ) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Wasatch Global Value Fund Q4 2025 Performance Review
01:18pm, Tuesday, 03'rd Mar 2026
Production volumes for Samsung's foundry business have been boosted by demand for HBM chips. Johnson & Johnson announced plans to spin its orthopedics business (joint replacements, surgical tools, etc
Retire Comfortably With These Dividend Growth Stocks
11:04am, Tuesday, 03'rd Mar 2026
Of all the retirement activities you can engage in, worrying about your financial security shouldn't be one of them.
Immunology, Neuroscience Step Up as Key Growth Engines for J&J
10:11am, Tuesday, 03'rd Mar 2026
JNJ's immunology and neuroscience units are driving growth, with Tremfya, Caplyta and Spravato offsetting Stelara's LOE hit.
Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)
08:03am, Tuesday, 03'rd Mar 2026
Fast Track designation reflects the unmet need in this serious disease and enables the potential for an accelerated FDA review timeline The designation is supported by a Phase 2 study in which nipoca
